Paradigm Biopharmaceuticals (ASX:PAR) received firm commitments to raise AU$16 million via the placement of 40 million shares at AU$0.40 apiece, according to a Monday filing with the Australian bourse.
The company also plans to issue one listed option for every four shares held under its loyalty option incentive program, exercisable at AU$0.65 and with a 12-month expiry, the filing said.
Proceeds will be used to fund a third phase clinical trial for osteoarthritis treatment using pentosan polysulfate sodium injections, starting in Australia in the first quarter of 2025 and expanding to US sites in the second quarter, according to the filing.
Shares fell 6% in afternoon trade Monday.
Price (AUD): $0.55, Change: $-0.04, Percent Change: -6.03%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.